Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies
Status:
Recruiting
Trial end date:
2025-04-17
Target enrollment:
Participant gender:
Summary
This study has two parts with distinct study objectives and study design. In part A,
odronextamab is studied as an intravenous (IV) administration with a dose escalation and a
dose expansion phase for B-NHL and CLL. The dose escalation phase for B-NHL and the CLL study
are closed at the time of protocol amendment 17. In part B, odronextamab is studied as a
subcutaneous (SC) administration with a dose finding and a dose expansion phase for B-NHL.